Sanuwave Health announced preliminary second-quarter 2026 revenue of $9.6 million to $9.8 million, exceeding the high end of its revised guidance of $8.5 million to $9.5 million. The result represents a decline of approximately 3% to 5% from $10.1 million in the same period last year. CEO Morgan Frank noted that capital sales faced headwinds from customer stress and a secondary market for used Ultramist systems, while consumable applicator sales set all-time records for both unit sales and revenues by significant margins. The company expects to report full second-quarter earnings in August.
SANUWAVE Health, Inc. Common StockConsumable applicator sales set all-time records for both unit sales and revenues by significant margins, indicating strong end-customer demand.